Scientist - Assay Development

Organization
Spark Therapeutics
Job Location
Philadelphia, PA
Job Description

RESPONSIBILITIES: 

Develop and implement new assays or optimize existing assays based on in-depth knowledge of laboratory techniques with guidance and supervision from the group leader 
Participate in validation of bioanalytical assays such as immunoassays, cell-based assays, and quantitative PCR assays 
Conduct clinical and preclinical sample analysis per SOPs and generate data with high scientific quality to meet GLP regulatory expectations 
Participate in sample management activities such as receiving, processing, storage, and shipping clinical and preclinical samples 
Work with senior staff to ensure the availability of adequate laboratory materials and qualify new reagents, as needed 
Participate in instrument maintenance and qualification 
Maintain accurate, timely and detailed records of work

Requirements: 

QUALIFICATIONS: 

Ability to learn new techniques and perform multiple tasks simultaneously 
Hands-on experience performing ELISA’s preferred 
Hands-on experience on Q-PCR or ELISpot is a plus 
Ability to work independently and as part of a team; self-motivation, adaptability, and a positive attitude 
Excellent organizational, communication and collaborations skills 
Keep accurate records, follow instructions, and comply with company policies 
Understanding of GLP principals is a plus 
REQUIREMENTS: 

Associate Scientist: B.A./B.S. in biological sciences and a minimum of 3 years relevant experience 
Scientist: M.S. in biological sciences with 3-5 years of relevant experience or a B.A./B.S. with 4-8 years of experience

Patricia Fara writes about childcare funding, and women in science and science history at NPR.

National Institute of Environmental Health Sciences researchers have visualized the career paths of former postdocs.

A new survey from the Pew Research Center finds that half of women working in STEM have experienced gender discrimination at work.

A proposal to tax students' tuition waivers no longer appears in the US tax bill, Vox reports.